|Director, Bioscience Synthetic Chemistry|
|Distinguished Professor, Chemistry and Biochemistry, Organic Chemistry|
|Member, Basic/Translational Research, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Molecular Biology Institute|
|Adjunct Faculty, Molecular & Medical Pharmacology|
|Researcher, Chemical Biology, Organic, Synthesis|
Mike Jung received his Bachelor of Arts in 1969 from Rice University, doing research with Richard Turner, and then his PhD in 1973 from Columbia, where he worked with Gilbert Stork. After a one-year NATO postdoctoral fellowship with Albert Eschenmoser at the ETH in Zurich, he joined the faculty at UCLA in 1974. He has risen through the ranks at UCLA and is now a Distinguished Professor of Chemistry. He has served as a reviewer of proposals for various organizations, e.g., NSF, PRF, NIH Medicinal Chemistry Study Section, Research Corporation and others. He is on the Scientific Advisory Boards of several pharmaceutical firms and consults currently for more than 20 industrial laboratories in both the biotech and big pharma settings. Professor Jung is an authority on synthetic organic and medicinal chemistry and has more than 25 patents arising from both his consulting activities and his own research. His current interests include the easy preparation of hindered systems via both Diels-Alder reactions using a new mixed Lewis acid catalyst and via an unusual formal [3,3]-sigmatropic rearrangement. He has also pioneered the use of epoxide rearrangements in synthesis (e.g., the non-aldol aldol) and has investigated new types of gem-disubstituent effects in synthesis. He has published more than 250 articles in refereed journals and has given over 470 lectures on his research, including lectures in German and French. Finally one of his recent compounds is in Phase 1/2a clinical trials for the treatment of hormone refractory prostate cancer.
Vigant Frederic, Hollmann Axel, Lee Jihye, Santos Nuno C, Jung Michael E, Lee Benhur The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses. Journal of virology. 2014; 88(3): 1849-53.
Kim Kyun-Do, Srikanth Sonal, Tan Yossan-Var, Yee Ma-Khin, Jew Marcus, Damoiseaux Robert, Jung Michael E, Shimizu Saki, An Dong Sung, Ribalet Bernard, Waschek James A, Gwack Yousang Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation. Journal of immunology (Baltimore, Md. : 1950). 2014; 192(1): 110-22.
Janzen Deanna M, Paik Daniel Y, Rosales Miguel A, Yep Brian, Cheng Donghui, Witte Owen N, Kayadibi Huseyin, Ryan Christopher M, Jung Michael E, Faull Kym, Memarzadeh Sanaz Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Molecular cancer therapeutics. 2013; 12(12): 2917-28.
Gillespie Eugene J, Ho Chi-Lee C, Balaji Kavitha, Clemens Daniel L, Deng Gang, Wang Yao E, Elsaesser Heidi J, Tamilselvam Batcha, Gargi Amandeep, Dixon Shandee D, France Bryan, Chamberlain Brian T, Blanke Steven R, Cheng Genhong, de la Torre Juan Carlos, Brooks David G, Jung Michael E, Colicelli John, Damoiseaux Robert, Bradley Kenneth A Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(50): E4904-12.
Zhong Wei, Springstead James R, Al-Mubarak Ramea, Lee Sangderk, Li Rongsong, Emert Benjamin, Berliner Judith A, Jung Michael E An epoxyisoprostane is a major regulator of endothelial cell function. Journal of medicinal chemistry. 2013; 56(21): 8521-32.
Rong Xin, Albert Carolyn J, Hong Cynthia, Duerr Mark A, Chamberlain Brian T, Tarling Elizabeth J, Ito Ayaka, Gao Jie, Wang Bo, Edwards Peter A, Jung Michael E, Ford David A, Tontonoz Peter LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell metabolism. 2013; 18(5): 685-97.
Chan Albert H, Wereszczynski Jeff, Amer Brendan R, Yi Sung Wook, Jung Michael E, McCammon J Andrew, Clubb Robert T Discovery of Staphylococcus aureus sortase A inhibitors using virtual screening and the relaxed complex scheme. Chemical biology & drug design. 2013; 82(4): 418-28.
Du Liutao, Jung Michael E, Damoiseaux Robert, Completo Gladys, Fike Francesca, Ku Jin-Mo, Nahas Shareef, Piao Cijing, Hu Hailiang, Gatti Richard A A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Molecular therapy : the journal of the American Society of Gene Therapy. 2013; 21(9): 1653-60.
Murphy Jennifer M, Armijo Amanda L, Nomme Julian, Lee Chi Hang, Smith Quentin A, Li Zheng, Campbell Dean O, Liao Hsiang-I, Nathanson David A, Austin Wayne R, Lee Jason T, Darvish Ryan, Wei Liu, Wang Jue, Su Ying, Damoiseaux Robert, Sadeghi Saman, Phelps Michael E, Herschman Harvey R, Czernin Johannes, Alexandrova Anastassia N, Jung Michael E, Lavie Arnon, Radu Caius G Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography. Journal of medicinal chemistry. 2013; 56(17): 6696-708.
Jung Michael E, Guzaev Mikhail Studies toward the enantiospecific total synthesis of rhodexin A. The Journal of organic chemistry. 2013; 78(15): 7518-26.
Williams Kevin J, Argus Joseph P, Zhu Yue, Wilks Moses Q, Marbois Beth N, York Autumn G, Kidani Yoko, Pourzia Alexandra L, Akhavan David, Lisiero Dominique N, Komisopoulou Evangelia, Henkin Amy H, Soto Horacio, Chamberlain Brian T, Vergnes Laurent, Jung Michael E, Torres Jorge Z, Liau Linda M, Christofk Heather R, Prins Robert M, Mischel Paul S, Reue Karen, Graeber Thomas G, Bensinger Steven J An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer research. 2013; 73(9): 2850-62.
Vigant Frederic, Lee Jihye, Hollmann Axel, Tanner Lukas B, Akyol Ataman Zeynep, Yun Tatyana, Shui Guanghou, Aguilar Hector C, Zhang Dong, Meriwether David, Roman-Sosa Gleyder, Robinson Lindsey R, Juelich Terry L, Buczkowski Hubert, Chou Sunwen, Castanho Miguel A R B, Wolf Mike C, Smith Jennifer K, Banyard Ashley, Kielian Margaret, Reddy Srinivasa, Wenk Markus R, Selke Matthias, Santos Nuno C, Freiberg Alexander N, Jung Michael E, Lee Benhur A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS pathogens. 2013; 9(4): e1003297.
Jung Michael E, Perez Felix, Regan Collin F, Yi Sung Wook, Perron Quentin Se-phenyl prop-2-eneselenoate: an ethylene equivalent for Diels-Alder reactions. Angewandte Chemie (International ed. in English). 2013; 52(7): 2060-2.